Buy Voxzogo (vosoritide)

What is Voxzogo (vosoritide) for?

Voxzogo (vosoritide) is an​​ FGFR3 inhibitor indicated to treat achondroplasia in patients 2 years and older whose epiphyses (growth plates of the bones) are not yet closed.^[1]

It is available in powder form, containing 0.4 mg, 0.56 mg or 1.2 mg powder vosoritide.^[1]

How does Voxzogo (vosoritide) work?

Achondroplasia is a growth condition in which the normal conversion of cartilage into bone does not occur, which leads to impaired bone growth. The cause for this condition is a change in the fibroblast growth factor receptor 3 gene (FGFR3), a negative regulator of bone growth. In achondroplasia patients, FGFR3 is permanently ‘switched on’, preventing bones from growing normally, which leads to bones that are shorter than normal.^[2]

The active ingredient in Voxzogo, vosoritide, can bind to a receptor called natriuretic peptide receptor type B (NPR-B), which inhibits FGFR3. Because of this, bones can grow normally, improving the symptoms of the disease.1,^[2]

Where has Voxzogo (vosoritide) been approved?

Voxzogo (vosoritide) was approved for the treatment of children with achondroplasia by:

• • The European Medicines Agency (EMA) on August 27, 2021.

^[3]

• • The Food and Drug Administration (FDA), USA on November 19, 20221.

^[4]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Voxzogo (vosoritide) taken?

The standard dosage is:^[1]

• • • 15 microgram (μg) per kg body weight.

Voxzogo (vosoritide) is given as an injection under the skin (subcutaneous) once a day, preferably around the same time of day.^[1]

Treatment should only start when achondroplasia is confirmed by genetic testing and should be stopped when the patient is not likely to grow any further.^[1]

If a dose of Voxzogo (vosoritide) is missed, it can be given within 12 hours. If more than 12 hours have passed since the original dosing schedule, the missed dose should NOT be given.^[1]

Complete information about Voxzogo (vosoritide) dosage and administration can be found in the official prescribing information listed in our references section.1

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Voxzogo (vosoritide)?

Common adverse reactions

The most common side effects (≥10% of patients) listed in the prescribing information include:^[1]

• • • Injection site reactions (such as swelling, redness, itching or pain)
    • Vomiting
    • Decreased blood pressure

Use in a specific population

The use of Voxzogo (vosoritide) is not recommended during pregnancy and breastfeeding. If you or your child are being treated with this medicine and are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [EMA]: Voxzogo (vosoritide) [PDF]
BioMarin Pharmaceutical, Aug 2021

2. Vosoritide for Achondroplasia
BioMarin, cited Sep 2021

3. European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
BioMarin, Aug 2021

4. BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
BioMarin, Nov 2021